eXoZymes (NASDAQ:EXOZ) Shares Climb 6.1% – Still a Buy?

Posted by Doug Wharley on Oct 4th, 2026

eXoZymes Inc. (NASDAQ:EXOZ – Get Free Report) shares shot up 6.1% during trading on Friday. The stock traded as high as $6.00 and last traded at $6.11. Approximately 2,117 shares were traded during trading, a decline of 73% from the average daily volume of 7,923 shares. The stock had previously closed at $5.76.

Analysts Set New Price Targets

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of eXoZymes in a report on Wednesday, August 26th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock presently has a consensus rating of “Sell”.

View Our Latest Analysis on eXoZymes

eXoZymes Stock Performance

The business’s 50-day simple moving average is $6.09 and its 200 day simple moving average is $7.72. The firm has a market cap of $56.82 million, a P/E ratio of -5.13 and a beta of 3.19. The company has a debt-to-equity ratio of 0.01, a quick ratio of 3.81 and a current ratio of 3.81.

eXoZymes (NASDAQ:EXOZ – Get Free Report) last issued its quarterly earnings data on Thursday, August 13th. The company reported ($0.33) EPS for the quarter. As a group, equities analysts predict that eXoZymes Inc. will post -1.19 earnings per share for the current year.

Institutional Investors Weigh In On eXoZymes

An institutional investor recently bought a new position in eXoZymes stock. BlackRock Inc. bought a new stake in shares of eXoZymes Inc. (NASDAQ:EXOZ – Free Report) during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 9,610 shares of the company’s stock, valued at approximately $81,000. BlackRock Inc. owned approximately 0.10% of eXoZymes as of its most recent filing with the Securities and Exchange Commission (SEC).

eXoZymes Company Profile

(Get Free Report)

eXoZymes, Inc is a development stage synthetic biochemical company. Its synthetic biology platform would enable the scalable exploration of many molecules and properties found in nature. The company was founded by Tyler Korman and Paul Opgenorth in April 2019 and is headquartered in Monrovia, NV.